The Experts below are selected from a list of 66 Experts worldwide ranked by ideXlab platform

Cédric Berney - One of the best experts on this subject based on the ideXlab platform.

  • relationship between clinical signs and lung function in horses with recurrent airway obstruction heaves during a bronchodilator trial
    Equine Veterinary Journal, 2010
    Co-Authors: N E Robinson, Michal A Olszewski, D Boehler, C Matson, Jani Hakala, Cédric Berney, Frederik J. Derksen
    Abstract:

    Summary During a trial to determine the dose response to the β2-adrenergic agonist Pirbuterol, we judged the severity of airway obstruction by use of a clinical scoring system and compared this to objective data obtained by quantitative measures of lung function. Six horses affected by recurrent airway obstruction were used in this trial. Four hundred and sixty-eight measurements of lung function and clinical scores were obtained from 13 measurement periods when horses received each of 6 doses of Pirbuterol. Scores of 1–4 were assigned to degree of nasal flaring and abdominal effort and summed for a total score. The veterinarian scoring the signs did not know the dose of Pirbuterol received by the horse and was unaware of the lung function data. Nasal, abdominal and total scores were significantly related to changes in lung function and changes in breathing pattern. There were significant differences between total scores greater than 5 in indices that reflected changes in breathing strategy (peak inspiratory and expiratory flow), peripheral airway obstruction (dynamic elastance), and effort of breathing (maximal change in pleural pressure). Below a total score of 5, there were fewer significant differences in lung function even though measurements of pulmonary resistance and dynamic elastance indicated considerable airway obstruction. Failure of clinical score to reflect this low-grade airway obstruction suggests that airway disease is underdiagnosed and its detection would be helped by the availability of a convenient lung function test.

  • use of a hand held metered dose aerosol delivery device to administer Pirbuterol acetate to horses with heaves
    Equine Veterinary Journal, 1996
    Co-Authors: F J Derksen, Michal A Olszewski, C Matson, Cédric Berney, N E Robinson, James W Lloyd, J Hakala, D T Ruth
    Abstract:

    Aerosol administration of bronchodilators to horses is recommended for treatment of certain airway diseases such as 'heaves'. We have developed a novel, hand-held, metered-dose inhaler and we sought to determine the bronchodilator efficacy of the beta 2 adrenoceptor agonist Pirbuterol delivered by this device to horses affected with 'heaves'. To induce airway obstruction, 6 heaves-susceptible horses were stabled, bedded on straw and fed hay. When the maximum change in pleural pressure during tidal breathing (delta Pplmax) was greater than 20 cmH2O on 2 consecutive days, pulmonary function was measured before and 5, 10 and 30 min, as well as 1, 2, 3, 4, 5, 6 and 7 h after administration of aerosol Pirbuterol. Pirbuterol was administered using a metered canister and the hand-held delivery device that was inserted into the left nostril. Either vehicle or Pirbuterol acetate (400, 600, 800, 1200 or 1600 micrograms) was administered to each horse. Relief of airway obstruction indicated by changes in pulmonary function was observed within 5 min after administration of both vehicle and Pirbuterol. Significant decreases in delta Pplmax and pulmonary resistance (RL) and an increase in dynamic compliance (Cdyn) persisted for the 7 h duration of the experiment. Comparison of the effect of vehicle and Pirbuterol at each time period showed that Pirbuterol decreased RL and delta Pplmax significantly for up to 1 h. The optimal dose was determined to be 600 micrograms. Immediate response to treatment, magnitude of drug effect and lack of side effects indicated that aerosol Pirbuterol is an effective and safe bronchodilator in horses with 'heaves'. The hand-held, metered-dose aerosol delivery device was very convenient and extremely effective and is, therefore, recommended for delivery of therapeutic aerosols to horses.

  • aerosol Pirbuterol bronchodilator activity and side effects in ponies with recurrent airway obstruction heaves
    Equine Veterinary Journal, 1992
    Co-Authors: F J Derksen, N E Robinson, Cédric Berney
    Abstract:

    The dose of aerosol Pirbuterol that could be administered safely to ponies (weight approximately 200 kg) was determined by observation for sweating, trembling and excitement and measurement of heart and respiratory rates during cumulative administration of the drug. Sweating, trembling and excitement were first observed following a dose of 2,400 micrograms and became more severe at 3,200 micrograms. These effects were accompanied by an increase in heart rate but not a change in respiratory rate. When 3200 micrograms was administered without prior administration of lower doses, side effects were trivial. This dose was therefore tested for its bronchodilator activity. Pulmonary function was evaluated in ponies that developed airway obstruction ('heaves') when housed in a barn and fed hay. Measurements were made when ponies were in clinical remission (Period A) and during an acute attack of airway obstruction (Period B). At Period A, Pirbuterol had no effect on pulmonary function. Barn housing increased pulmonary resistance and decreased dynamic compliance. At Measurement Period B, Pirbuterol administration significantly reduced pulmonary resistance and increased dynamic compliance and minute ventilation. These changes were significant 5 min after drug administration and lasted for the 30 min duration of the study. Vehicle administration had no effect on pulmonary function. It was concluded that aerosol Pirbuterol has few undesirable side effects and is an effective bronchodilator in ponies with recurrent airway obstruction.

N E Robinson - One of the best experts on this subject based on the ideXlab platform.

  • relationship between clinical signs and lung function in horses with recurrent airway obstruction heaves during a bronchodilator trial
    Equine Veterinary Journal, 2010
    Co-Authors: N E Robinson, Michal A Olszewski, D Boehler, C Matson, Jani Hakala, Cédric Berney, Frederik J. Derksen
    Abstract:

    Summary During a trial to determine the dose response to the β2-adrenergic agonist Pirbuterol, we judged the severity of airway obstruction by use of a clinical scoring system and compared this to objective data obtained by quantitative measures of lung function. Six horses affected by recurrent airway obstruction were used in this trial. Four hundred and sixty-eight measurements of lung function and clinical scores were obtained from 13 measurement periods when horses received each of 6 doses of Pirbuterol. Scores of 1–4 were assigned to degree of nasal flaring and abdominal effort and summed for a total score. The veterinarian scoring the signs did not know the dose of Pirbuterol received by the horse and was unaware of the lung function data. Nasal, abdominal and total scores were significantly related to changes in lung function and changes in breathing pattern. There were significant differences between total scores greater than 5 in indices that reflected changes in breathing strategy (peak inspiratory and expiratory flow), peripheral airway obstruction (dynamic elastance), and effort of breathing (maximal change in pleural pressure). Below a total score of 5, there were fewer significant differences in lung function even though measurements of pulmonary resistance and dynamic elastance indicated considerable airway obstruction. Failure of clinical score to reflect this low-grade airway obstruction suggests that airway disease is underdiagnosed and its detection would be helped by the availability of a convenient lung function test.

  • use of a hand held metered dose aerosol delivery device to administer Pirbuterol acetate to horses with heaves
    Equine Veterinary Journal, 1996
    Co-Authors: F J Derksen, Michal A Olszewski, C Matson, Cédric Berney, N E Robinson, James W Lloyd, J Hakala, D T Ruth
    Abstract:

    Aerosol administration of bronchodilators to horses is recommended for treatment of certain airway diseases such as 'heaves'. We have developed a novel, hand-held, metered-dose inhaler and we sought to determine the bronchodilator efficacy of the beta 2 adrenoceptor agonist Pirbuterol delivered by this device to horses affected with 'heaves'. To induce airway obstruction, 6 heaves-susceptible horses were stabled, bedded on straw and fed hay. When the maximum change in pleural pressure during tidal breathing (delta Pplmax) was greater than 20 cmH2O on 2 consecutive days, pulmonary function was measured before and 5, 10 and 30 min, as well as 1, 2, 3, 4, 5, 6 and 7 h after administration of aerosol Pirbuterol. Pirbuterol was administered using a metered canister and the hand-held delivery device that was inserted into the left nostril. Either vehicle or Pirbuterol acetate (400, 600, 800, 1200 or 1600 micrograms) was administered to each horse. Relief of airway obstruction indicated by changes in pulmonary function was observed within 5 min after administration of both vehicle and Pirbuterol. Significant decreases in delta Pplmax and pulmonary resistance (RL) and an increase in dynamic compliance (Cdyn) persisted for the 7 h duration of the experiment. Comparison of the effect of vehicle and Pirbuterol at each time period showed that Pirbuterol decreased RL and delta Pplmax significantly for up to 1 h. The optimal dose was determined to be 600 micrograms. Immediate response to treatment, magnitude of drug effect and lack of side effects indicated that aerosol Pirbuterol is an effective and safe bronchodilator in horses with 'heaves'. The hand-held, metered-dose aerosol delivery device was very convenient and extremely effective and is, therefore, recommended for delivery of therapeutic aerosols to horses.

  • aerosol Pirbuterol bronchodilator activity and side effects in ponies with recurrent airway obstruction heaves
    Equine Veterinary Journal, 1992
    Co-Authors: F J Derksen, N E Robinson, Cédric Berney
    Abstract:

    The dose of aerosol Pirbuterol that could be administered safely to ponies (weight approximately 200 kg) was determined by observation for sweating, trembling and excitement and measurement of heart and respiratory rates during cumulative administration of the drug. Sweating, trembling and excitement were first observed following a dose of 2,400 micrograms and became more severe at 3,200 micrograms. These effects were accompanied by an increase in heart rate but not a change in respiratory rate. When 3200 micrograms was administered without prior administration of lower doses, side effects were trivial. This dose was therefore tested for its bronchodilator activity. Pulmonary function was evaluated in ponies that developed airway obstruction ('heaves') when housed in a barn and fed hay. Measurements were made when ponies were in clinical remission (Period A) and during an acute attack of airway obstruction (Period B). At Period A, Pirbuterol had no effect on pulmonary function. Barn housing increased pulmonary resistance and decreased dynamic compliance. At Measurement Period B, Pirbuterol administration significantly reduced pulmonary resistance and increased dynamic compliance and minute ventilation. These changes were significant 5 min after drug administration and lasted for the 30 min duration of the study. Vehicle administration had no effect on pulmonary function. It was concluded that aerosol Pirbuterol has few undesirable side effects and is an effective bronchodilator in ponies with recurrent airway obstruction.

F J Derksen - One of the best experts on this subject based on the ideXlab platform.

  • use of a hand held metered dose aerosol delivery device to administer Pirbuterol acetate to horses with heaves
    Equine Veterinary Journal, 1996
    Co-Authors: F J Derksen, Michal A Olszewski, C Matson, Cédric Berney, N E Robinson, James W Lloyd, J Hakala, D T Ruth
    Abstract:

    Aerosol administration of bronchodilators to horses is recommended for treatment of certain airway diseases such as 'heaves'. We have developed a novel, hand-held, metered-dose inhaler and we sought to determine the bronchodilator efficacy of the beta 2 adrenoceptor agonist Pirbuterol delivered by this device to horses affected with 'heaves'. To induce airway obstruction, 6 heaves-susceptible horses were stabled, bedded on straw and fed hay. When the maximum change in pleural pressure during tidal breathing (delta Pplmax) was greater than 20 cmH2O on 2 consecutive days, pulmonary function was measured before and 5, 10 and 30 min, as well as 1, 2, 3, 4, 5, 6 and 7 h after administration of aerosol Pirbuterol. Pirbuterol was administered using a metered canister and the hand-held delivery device that was inserted into the left nostril. Either vehicle or Pirbuterol acetate (400, 600, 800, 1200 or 1600 micrograms) was administered to each horse. Relief of airway obstruction indicated by changes in pulmonary function was observed within 5 min after administration of both vehicle and Pirbuterol. Significant decreases in delta Pplmax and pulmonary resistance (RL) and an increase in dynamic compliance (Cdyn) persisted for the 7 h duration of the experiment. Comparison of the effect of vehicle and Pirbuterol at each time period showed that Pirbuterol decreased RL and delta Pplmax significantly for up to 1 h. The optimal dose was determined to be 600 micrograms. Immediate response to treatment, magnitude of drug effect and lack of side effects indicated that aerosol Pirbuterol is an effective and safe bronchodilator in horses with 'heaves'. The hand-held, metered-dose aerosol delivery device was very convenient and extremely effective and is, therefore, recommended for delivery of therapeutic aerosols to horses.

  • aerosol Pirbuterol bronchodilator activity and side effects in ponies with recurrent airway obstruction heaves
    Equine Veterinary Journal, 1992
    Co-Authors: F J Derksen, N E Robinson, Cédric Berney
    Abstract:

    The dose of aerosol Pirbuterol that could be administered safely to ponies (weight approximately 200 kg) was determined by observation for sweating, trembling and excitement and measurement of heart and respiratory rates during cumulative administration of the drug. Sweating, trembling and excitement were first observed following a dose of 2,400 micrograms and became more severe at 3,200 micrograms. These effects were accompanied by an increase in heart rate but not a change in respiratory rate. When 3200 micrograms was administered without prior administration of lower doses, side effects were trivial. This dose was therefore tested for its bronchodilator activity. Pulmonary function was evaluated in ponies that developed airway obstruction ('heaves') when housed in a barn and fed hay. Measurements were made when ponies were in clinical remission (Period A) and during an acute attack of airway obstruction (Period B). At Period A, Pirbuterol had no effect on pulmonary function. Barn housing increased pulmonary resistance and decreased dynamic compliance. At Measurement Period B, Pirbuterol administration significantly reduced pulmonary resistance and increased dynamic compliance and minute ventilation. These changes were significant 5 min after drug administration and lasted for the 30 min duration of the study. Vehicle administration had no effect on pulmonary function. It was concluded that aerosol Pirbuterol has few undesirable side effects and is an effective bronchodilator in ponies with recurrent airway obstruction.

David Steele - One of the best experts on this subject based on the ideXlab platform.

  • nonbronchodilator effects of Pirbuterol and ipratropium in chronic obstructive pulmonary disease
    Chest, 1995
    Co-Authors: Kumar Ashutosh, Gautam Dev, David Steele
    Abstract:

    Background Although both beta-adrenergic agonists and anticholinergic agents are widely used in the treatment of patients with COPD, they influence the pulmonary circulation and ventilation differently. We compared the effects of these two agents on gas exchange and distribution of ventilation in COPD. Methods Pirbuterol and ipratropium bromide were administered by inhalation via a metered-dose inhaler to 12 and 14 patients with COPD, respectively, in a randomized, double-blind fashion. Pulmonary function tests, arterial blood gas levels, heart rate, resting minute ventilation (V¨ E ), physiologic dead space volume to total ventilation ratio (VD/Vt) and oxygen consumption (V¨o 2 ) were measured prior to and then 5, 15, 30, and 60 min after administration of the respective drugs. The changes in these measurements after administration of the two drugs were analyzed and compared with each other. Results The pulmonary function test measurements showed similar improvement after administration of both drugs. Heart rate fell in both groups. After administration of Pirbuterol, the alveolar-arterial oxygen pressure difference (P[A-a]O 2 ) and V¨ E rose significantly and the rise in FEV 1 showed a negative correlation with the fall in PaO 2 . In contrast, the use of ipratropium bromide did not produce these effects, but resulted in a fall in V¨o 2 and a rise in VD/Vt . Conclusion Pirbuterol and ipratropium are equally effective bronchodilators in COPD. Pirbuterol results in a significant rise in P(A-a)O 2 and resting V¨ I . Ipratropium does not affect these measurements and seems to reduce the oxygen cost of breathing. The results suggest significant differences between the effects of the two agents on gas exchange, ventilation, and V¨o 2 which could be of clinical significance.

Janet B. Croft - One of the best experts on this subject based on the ideXlab platform.